Hiroyoshi Takemoto1, Junichi Nishimura2, Takamichi Komori3, Ho Min Kim4, Hirofumi Ota5, Rei Suzuki6, Masakazu Ikenaga7, Masataka Ikeda8, Hirofumi Yamamoto9, Taroh Satoh10, Taishi Hata11, Ichiro Takemasa11, Tsunekazu Mizushima11, Yuichirou Doki11, Masaki Mori11. 1. Department of Surgery, Kinki Central Hospital, Kurumaduka 3-1, Itami, Hyogo, Japan. 2. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan. jnishimura@gesurg.med.osaka-u.ac.jp. 3. Department of Surgery, Toyonaka Municipal Hospital, Shibahara 4-14-1, Toyonaka, Osaka, Japan. 4. Department of Surgery, Rinku General Medical Center, Rinku Ourai Kita 2-23, Izumisano, Osaka, Japan. 5. Department of Digestive Surgery, Ikeda City Hospital, Jyounan 3-1-18, Ikeda, Osaka, Japan. 6. Department of Surgery, Itami City Hospital, Koyaike 1-100, Itami, Hyogo, Japan. 7. Department of Surgery, Higashiosaka City General Hospital, Nishiiwata 3-4-5, Higashiosaka, Osaka, Japan. 8. Department of Surgery, National Hospital Organization, Osaka National Hospital, Hoenzaka 2-1-14, Osaka, Osaka, Japan. 9. Division of Health Sciences, Graduate School of Medicine, Department of Molecular Pathology, Osaka University, Yamadaoka 1-7, Suita, Osaka, Japan. 10. Department of Frontier-Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, Japan. 11. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan.
Abstract
BACKGROUND: We previously reported in the SENRI trial on the usefulness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer patients receiving anoxaliplatin-based regimen which is classified as moderately emetogenic cancer chemotherapy. In the present subgroup analysis of the SENRI trial, we assessed the risk factors for CINV in colorectal cancer patients who receivedoxaliplatin-based chemotherapy. METHODS: Multivariate logistic regression models were used to assess the impact of aprepitant use and patient characteristics on vomiting and nausea. We also assessed the proportion of CINV in patients by gender. RESULTS: Female gender and aprepitant use were associated with the incidence of vomiting and no significant nausea. Significantly more men achieved no vomiting than women (92.9 vs 84.5 % in men and women, respectively; P = 0.0001). The rate of no nausea, complete response, complete protection, and total control was also higher in men. The rate rescue therapy use was significantly higher in women than men. We compared the rate of CINV between aprepitant and control groups and found a significant difference in male patients who achieved no vomiting and complete protection in the overall phase. In women, the rate of no nausea, no vomiting, and total control was higher in the aprepitant group than in the control group. CONCLUSIONS: Gender and aprepitant use were risk factors for CINV in colorectal patients who received oxaliplatin-based chemotherapy. Aprepitant therapy was more effective for women than for men in the prevention of CINV in colorectal cancer patients receiving anoxaliplatin-based regimen.
RCT Entities:
BACKGROUND: We previously reported in the SENRI trial on the usefulness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in colorectal cancerpatients receiving an oxaliplatin-based regimen which is classified as moderately emetogenic cancer chemotherapy. In the present subgroup analysis of the SENRI trial, we assessed the risk factors for CINV in colorectal cancerpatients who received oxaliplatin-based chemotherapy. METHODS: Multivariate logistic regression models were used to assess the impact of aprepitant use and patient characteristics on vomiting and nausea. We also assessed the proportion of CINV in patients by gender. RESULTS: Female gender and aprepitant use were associated with the incidence of vomiting and no significant nausea. Significantly more men achieved no vomiting than women (92.9 vs 84.5 % in men and women, respectively; P = 0.0001). The rate of no nausea, complete response, complete protection, and total control was also higher in men. The rate rescue therapy use was significantly higher in women than men. We compared the rate of CINV between aprepitant and control groups and found a significant difference in male patients who achieved no vomiting and complete protection in the overall phase. In women, the rate of no nausea, no vomiting, and total control was higher in the aprepitant group than in the control group. CONCLUSIONS: Gender and aprepitant use were risk factors for CINV in colorectalpatients who received oxaliplatin-based chemotherapy. Aprepitant therapy was more effective for women than for men in the prevention of CINV in colorectal cancerpatients receiving an oxaliplatin-based regimen.
Authors: F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; P Feyer; S M Grunberg; P J Hesketh; K Jordan; M G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr Journal: Ann Oncol Date: 2010-05 Impact factor: 32.976
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Jane T Hickok; Joseph A Roscoe; Gary R Morrow; Christopher W Bole; Hongwei Zhao; Karen L Hoelzer; Shaker R Dakhil; Timothy Moore; Tom R Fitch Journal: Lancet Oncol Date: 2005-09-13 Impact factor: 41.316
Authors: Paul J Hesketh; Jerry Younger; Pedro Sanz-Altamira; Melissa Hayden; Julie Bushey; Brian Trainor; Michael Krentzin; Peter Nowd; Konstantinos Arnaoutakis; Ann M Hesketh Journal: Support Care Cancer Date: 2008-12-06 Impact factor: 3.603
Authors: F Roila; M Tonato; C Basurto; M Picciafuoco; S Bracarda; D Donati; P Malacarne; L Monici; F Di Costanzo; L Patoia Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: Joseph S Bubalo; Jon D Herrington; Marc Takemoto; Patricia Willman; Michael S Edwards; Casey Williams; Alan Fisher; Alison Palumbo; Eric Chen; Charles Blanke; Charles D Lopez Journal: Support Care Cancer Date: 2017-10-31 Impact factor: 3.603